55 results
Page 2 of 3
POS AM
oxwwnvf t6953p
18 Oct 21
Prospectus update (post-effective amendment)
5:29pm
POS AM
pvtf 5lanf9c3c
15 Oct 21
Prospectus update (post-effective amendment)
7:50am
F-3
mzb2v5
15 Oct 21
Shelf registration (foreign)
7:41am
6-K/A
EX-99.1
neljpihei qmb
15 Oct 21
Current report (foreign) (amended)
7:19am
6-K
EX-99.2
77k1 h5ygvcbyx
15 Oct 21
Notice of General Meeting to be held on 1 November 2021
7:15am
6-K
EX-99.1
mhz49jv87y4k1v8te
12 Aug 21
Current report (foreign)
4:38pm
6-K
EX-99.1
ngvgv52d4xor
12 Aug 21
Silence Therapeutics Reports Half-Year 2021 Results
4:30pm
6-K
EX-99.1
ybfwwi 5kwea
25 May 21
Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration
6:30am
6-K
EX-99.2
um7jy
19 May 21
Silence Therapeutics Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers
6:30am
6-K
EX-99.2
x53 wnrqwuzu60
7 May 21
Notice of Annual General Meeting
4:18pm
20-F/A
sfk iyfyh5kd
29 Apr 21
Annual report (foreign) (amended)
4:26pm
6-K
EX-99.1
lrlsp ieaf
29 Apr 21
Silence Therapeutics Announces First Patient Dosed in GEMINI II Phase I Clinical Trial for SLN124
6:30am
424B4
nwqt03tx
12 Apr 21
Prospectus supplement with pricing info
11:12am
424B4
5kl abcor
12 Apr 21
Prospectus supplement with pricing info
11:11am
POS AM
zrzo3kc5dnht9njfx
8 Apr 21
Prospectus update (post-effective amendment)
9:31am
POS AM
wtdgos75umj ulq79w6b
8 Apr 21
Prospectus update (post-effective amendment)
9:18am
20-F
x59 z7hk01
30 Mar 21
Annual report (foreign)
5:22pm
6-K
EX-99.1
n2k4cmbkax
30 Mar 21
Silence Therapeutics Reports Full-year 2020 Results
7:47am
424B7
6on4dom5nfvu
15 Mar 21
Prospectus with selling stockholder info
10:07am
F-1/A
lry9xn 9yqr
11 Mar 21
Registration statement (foreign) (amended)
4:02pm